{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:48:43Z","timestamp":1773971323584,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["PTDC\/MED-QUI\/29036\/2017"],"award-info":[{"award-number":["PTDC\/MED-QUI\/29036\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["EXPL\/BIA-BFS\/1034\/2021"],"award-info":[{"award-number":["EXPL\/BIA-BFS\/1034\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["CEECIND\/03247\/2018"],"award-info":[{"award-number":["CEECIND\/03247\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UID\/00100\/2025"],"award-info":[{"award-number":["UID\/00100\/2025"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UID\/PRR\/100\/2025"],"award-info":[{"award-number":["UID\/PRR\/100\/2025"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xphs.2025.104151","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:07:27Z","timestamp":1767139647000},"page":"104151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interaction of isoniazid derivatives active against drug-resistant tuberculosis with models of the lung surfactant and of the Mycobacterium tuberculosis cell wall"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7206-9566","authenticated-orcid":false,"given":"Weronika","family":"\u015ali\u017cewska","sequence":"first","affiliation":[]},{"given":"Filomena","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Rodrigo F.M.","family":"de Almeida","sequence":"additional","affiliation":[]},{"given":"Joaquim T.","family":"Marqu\u00eas","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2025.104151_bib0001","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ni981","article-title":"Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis","volume":"4","author":"Hingley-Wilson","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.xphs.2025.104151_bib0002","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3390\/ph5111210","article-title":"The role of transport mechanisms in mycobacterium tuberculosis drug resistance and tolerance","volume":"5","author":"Sarathy","year":"2012","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.xphs.2025.104151_bib0003","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MGM2-0003-2013","article-title":"The molecular genetics of mycolic acid biosynthesis","volume":"2","author":"Pawe\u0141czyk","year":"2014","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.xphs.2025.104151_bib0004","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1017\/S0031182016002377","article-title":"Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target","volume":"145","author":"Abrahams","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.xphs.2025.104151_bib0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41579-019-0273-7","article-title":"The mycobacterial cell envelope \u2014 a moving target","volume":"18","author":"Dulberger","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.xphs.2025.104151_bib0006","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0065-2911(08)60016-8","article-title":"The envelope layers of mycobacteria with reference to their pathogenicity","volume":"39","author":"Daff\u00e9","year":"1998","journal-title":"Adv Microb Physiol"},{"key":"10.1016\/j.xphs.2025.104151_bib0007","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0163-7827(98)00008-3","article-title":"Mycolic acids: structure, biosynthesis and physiological functions","volume":"37","author":"Barry","year":"1998","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.xphs.2025.104151_bib0008","series-title":"New Insights in Antibiotic Resistance and Pneumococcal Vaccines","article-title":"Mechanisms and action of drug resistance on Mycobacterium tuberculosis","author":"Brammachary","year":"2022"},{"key":"10.1016\/j.xphs.2025.104151_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101106","article-title":"Flying blind: urgency for drug-resistant testing for new tuberculosis drugs","volume":"6","author":"Quansah","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.xphs.2025.104151_bib0010","series-title":"Pulmonary Surfactant: From Molecular Biology to Clinical Practice","first-page":"109","article-title":"Physical chemistry of pulmonary surfactant in the terminal air spaces","author":"Keough","year":"1992"},{"key":"10.1016\/j.xphs.2025.104151_bib0011","series-title":"From Molecular Biology to Clinical Practice","first-page":"165","article-title":"Surfactant and lung mechanics, pulmonary surfactant","author":"Goerke","year":"1992"},{"key":"10.1016\/j.xphs.2025.104151_bib0012","series-title":"Physicochemical Aspects of Pulmonary Surfactant, Fetal and Neonatal Physiology","first-page":"1014","author":"Possmayer","year":"2004"},{"key":"10.1016\/j.xphs.2025.104151_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.178064","article-title":"Pulmonary surfactant in asthma","volume":"1005","author":"Blanco","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.xphs.2025.104151_bib0014","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jconrel.2018.10.012","article-title":"Pulmonary surfactant and drug delivery: focusing on the role of surfactant proteins","volume":"291","author":"Guagliardo","year":"2018","journal-title":"J Control Rel"},{"key":"10.1016\/j.xphs.2025.104151_bib0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0925-4439(98)00061-1","article-title":"The role of lipids in pulmonary surfactant","volume":"1408","author":"Veldhuizen","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.xphs.2025.104151_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.108850","article-title":"Structural hallmarks of lung surfactant: lipid-protein interactions, membrane structure and future challenges","volume":"703","author":"Castillo-S\u00e1nchez","year":"2021","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.xphs.2025.104151_bib0017","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.bbamem.2008.03.021","article-title":"Current perspectives in pulmonary surfactant \u2014 inhibition, enhancement and evaluation","volume":"1778","author":"Zuo","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.xphs.2025.104151_bib0018","first-page":"3789","article-title":"Spectroscopic and molecular docking study on specific binding and inhibition of isoniazid to human serum albumin and catalase","volume":"36","author":"Wang","year":"2016","journal-title":"Guang Pu Xue Yu Guang Pu Fen Xi"},{"key":"10.1016\/j.xphs.2025.104151_bib0019","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1128\/AAC.35.6.1035","article-title":"Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum","volume":"35","author":"Qu\u00e9mard","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2025.104151_bib0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.chemphyslip.2014.07.002","article-title":"Interactions of isoniazid with membrane models: implications for drug mechanism of action","volume":"183","author":"Pinheiro","year":"2014","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.xphs.2025.104151_bib0021","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1021\/acs.molpharmaceut.7b00719","article-title":"Insights on the mechanism of action of INH-C(10) as an antitubercular prodrug","volume":"14","author":"Vila-Vi\u00e7osa","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2025.104151_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106986","article-title":"Membrane interaction studies of isoniazid derivatives active against drug-resistant tuberculosis","volume":"205","author":"Terreiro","year":"2025","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104151_bib0023","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.colsurfa.2012.02.013","article-title":"Membrane affinity of antituberculotic drug conjugate using lipid monolayer containing mycolic acid","volume":"413","author":"P\u00e9nzes","year":"2012","journal-title":"Colloids Surf A"},{"key":"10.1016\/j.xphs.2025.104151_bib0024","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejmech.2014.04.077","article-title":"Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity","volume":"81","author":"Martins","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.xphs.2025.104151_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.868545","article-title":"In vitro evaluation of isoniazid derivatives as potential agents against drug-resistant tuberculosis","volume":"13","author":"Marqu\u00eas","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.xphs.2025.104151_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2020.124820","article-title":"Lipophilicity assessment of some isoniazid derivatives active against Mycobacterium tuberculosis","volume":"599","author":"Santos","year":"2020","journal-title":"Colloids Surf A"},{"key":"10.1016\/j.xphs.2025.104151_bib0027","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xphs.2025.104151_bib0028","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1021\/acsptsci.2c00115","article-title":"Using human serum albumin binding affinities as a proactive strategy to affect the pharmacodynamics and pharmacokinetics of preclinical drug candidates","volume":"5","author":"Fan","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.xphs.2025.104151_bib0029","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2016.05.011","article-title":"Dry powder inhalable formulations for anti-tubercular therapy","volume":"102","author":"Parumasivam","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2025.104151_bib0030","first-page":"15","article-title":"Inhalable combination powder formulations for treating latent and multidrug-resistant tuberculosis: formulation and in vitro characterization","author":"Eedara","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2025.104151_bib0031","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s13346-022-01238-y","article-title":"A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation","volume":"13","author":"Khadka","year":"2023","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.xphs.2025.104151_bib0032","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4155\/tde-2017-0050","article-title":"Drug delivery for tuberculosis: is inhaled therapy the key to success?","volume":"8","author":"Traini","year":"2017","journal-title":"Ther Deliv"},{"key":"10.1016\/j.xphs.2025.104151_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2022.102228","article-title":"Dry powder inhalers of antitubercular drugs","volume":"135","author":"Nainwal","year":"2022","journal-title":"Tuberculosis"},{"key":"10.1016\/j.xphs.2025.104151_bib0034","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.bbamem.2012.09.015","article-title":"Interplay of mycolic acids, antimycobacterial compounds and pulmonary surfactant membrane: a biophysical approach to disease","volume":"1828","author":"Pinheiro","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.xphs.2025.104151_bib0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.colsurfb.2008.01.023","article-title":"Monolayers of the lipid derivatives of isoniazid at the air\/water interface and the formation of self-assembled nanostructures in water","volume":"64","author":"Jin","year":"2008","journal-title":"Colloids Surf B"},{"key":"10.1016\/j.xphs.2025.104151_bib0036","doi-asserted-by":"crossref","first-page":"11635","DOI":"10.1021\/jp303725j","article-title":"Molecular interaction of rifabutin on model lung surfactant monolayers","volume":"116","author":"Pinheiro","year":"2012","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.xphs.2025.104151_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2024.110178","article-title":"Searching for the role of membrane lipids in the mechanism of antibacterial effect of hinokitiol","volume":"761","author":"Wy\u017cga","year":"2024","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.xphs.2025.104151_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2024.135411","article-title":"The influence of blackcurrant extract\u2013based cosmetic antimicrobial agent on skin cells and skin model membranes","volume":"703","author":"Wy\u017cga","year":"2024","journal-title":"Colloids Surf A"},{"key":"10.1016\/j.xphs.2025.104151_bib0039","article-title":"Interactions of hinokitiol with fungal membrane lipids in model systems","volume":"1867","author":"Wy\u017cga","year":"2025","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.xphs.2025.104151_bib0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejpb.2014.12.001","article-title":"Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome","volume":"89","author":"Patel","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2025.104151_bib0041","doi-asserted-by":"crossref","first-page":"e1586","DOI":"10.1002\/wnan.1586","article-title":"Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases","volume":"12","author":"Anderson","year":"2020","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"10.1016\/j.xphs.2025.104151_bib0042","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.bj.2022.03.001","article-title":"A recipe for a good clinical pulmonary surfactant","volume":"45","author":"P\u00e9rez-Gil","year":"2022","journal-title":"Biomed J"},{"key":"10.1016\/j.xphs.2025.104151_bib0043","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0006-3495(04)74106-5","article-title":"Effect of pulmonary surfactant protein SP-B on the micro- and nanostructure of phospholipid films","volume":"86","author":"Cruz","year":"2004","journal-title":"Biophys J"},{"key":"10.1016\/j.xphs.2025.104151_bib0044","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.bbamem.2016.02.030","article-title":"Computer simulations of lung surfactant","volume":"1858","author":"Baoukina","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.xphs.2025.104151_bib0045","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"Dartois","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.xphs.2025.104151_bib0046","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1021\/la011840+","article-title":"Characterization of the liquid-expanded to liquid-condensed phase transition of monolayers by means of compressibility","volume":"18","author":"Yu","year":"2002","journal-title":"Langmuir"},{"key":"10.1016\/j.xphs.2025.104151_bib0047","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.1021\/acs.langmuir.5b01775","article-title":"Detailed analysis of the surface area and elasticity in the saturated 1,2-diacylphosphatidylcholine\/cholesterol binary monolayer system","volume":"31","author":"Miyoshi","year":"2015","journal-title":"Langmuir"},{"key":"10.1016\/j.xphs.2025.104151_bib0048","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1103\/RevModPhys.71.779","article-title":"Structure and phase transitions in Langmuir monolayers","volume":"71","author":"Kaganer","year":"1999","journal-title":"Rev Mod Phys"},{"key":"10.1016\/j.xphs.2025.104151_bib0049","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216252","article-title":"Unraveling complex hysteresis phenomenon in 1,2-dipalmitoyl-sn-glycero-3-phosphocholine monolayer: insight into factors influencing surface dynamics","volume":"24","author":"Sudjarwo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xphs.2025.104151_bib0050","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1021\/je200827u","article-title":"Acidity and hydrophobicity of several new potential antitubercular drugs: isoniazid and benzimidazole derivatives","volume":"57","author":"R\u00e0fols","year":"2012","journal-title":"J Chem Eng Data"},{"key":"10.1016\/j.xphs.2025.104151_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e04545","article-title":"Interaction of different lipoprotein types with cholesterol at the air\/water interface","volume":"6","author":"Ninomiya","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.xphs.2025.104151_bib0052","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0006-3495(96)79629-7","article-title":"The interfacial elastic packing interactions of galactosylceramides, sphingomyelins, and phosphatidylcholines","volume":"70","author":"Smaby","year":"1996","journal-title":"Biophys J"},{"key":"10.1016\/j.xphs.2025.104151_bib0053","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.molstruc.2013.08.029","article-title":"Isoniazid interaction with phosphatidylcholine-based membranes","volume":"1051","author":"Marques","year":"2013","journal-title":"J Mol Struct"},{"key":"10.1016\/j.xphs.2025.104151_bib0054","series-title":"The Structure of Biological Membranes","first-page":"19","article-title":"The mesomorphic phase behavior of lipid bilayers","author":"McElhaney","year":"2011"},{"key":"10.1016\/j.xphs.2025.104151_bib0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/jrms.JRMS_904_17","article-title":"Mycobacterium tuberculosis and lipids: Insights into molecular mechanisms from persistence to virulence","volume":"23","author":"Ghazaei","year":"2018","journal-title":"J Res Med Sci"},{"key":"10.1016\/j.xphs.2025.104151_bib0056","doi-asserted-by":"crossref","first-page":"7325","DOI":"10.1021\/la0004606","article-title":"Conformational characterization of \u03b1-mycolic acid in a monolayer film by the Langmuir\u2212Blodgett technique and atomic force microscopy","volume":"16","author":"Hasegawa","year":"2000","journal-title":"Langmuir"},{"key":"10.1016\/j.xphs.2025.104151_bib0057","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.chemphyslip.2010.04.010","article-title":"Differential conformational behaviors of \u03b1-mycolic acids in Langmuir monolayers and computer simulations","volume":"163","author":"Villeneuve","year":"2010","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.xphs.2025.104151_bib0058","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.2c00321","article-title":"Effect of cisplatin and its cationic analogues in the phase behavior and permeability of model lipid bilayers","author":"Martinho","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2025.104151_bib0059","article-title":"Assessing the role of membrane lipids in the action of ruthenium(III) anticancer compounds","volume":"9","author":"Starosta","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.xphs.2025.104151_bib0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/membranes11010024","article-title":"Unraveling the role of drug-lipid interactions in nsaids-induced cardiotoxicity","volume":"11","author":"Pereira-Leite","year":"2021","journal-title":"Membranes"},{"key":"10.1016\/j.xphs.2025.104151_bib0061","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1021\/acschembio.5c00330","article-title":"Systematic determination of the impact of structural edits on peptide accumulation into mycobacteria","volume":"20","author":"Dash","year":"2025","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.xphs.2025.104151_bib0062","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevE.100.022801","article-title":"Emergence of a linear slope region of the isotherm in the first-order liquid-expanded\u2013liquid-condensed phase transition in Langmuir monolayers","volume":"100","author":"Hatta","year":"2019","journal-title":"Phys Rev E"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925006057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925006057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:30:38Z","timestamp":1773966638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925006057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0022354925006057"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104151","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interaction of isoniazid derivatives active against drug-resistant tuberculosis with models of the lung surfactant and of the Mycobacterium tuberculosis cell wall","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104151"}}